Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,037 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cancer Screening Clear all
Completed Not applicable Interventional

High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)

NCT04191655
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colon Dysplasia, Ulcerative Colitis, Crohn Colitis, Indeterminate Colitis
Interventions
High Definition Colonoscopy, Dye Spraying Chromocolonoscopy
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Rural Indiana Screening for Colorectal Cancer

NCT06133439
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colorectal Screen rates with implementation of evidence-based intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
45 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Monroe, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting No phase listed Observational

Nashville Early Diagnosis Lung Cancer Project

NCT01475500
View directory record Official record
Conditions
Lung Cancer
Interventions
Sputum sample, Pulmonary function tests, Computerized tomography (CT) scan of the chest, Buccal epithelium collection, Nasal brushings, Bronchoscopy, Bronchoalveolar lavage, Blood sample collection, Urine sample, Questionnaire-data collection
Procedure · Radiation · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
55 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening

NCT04585919
View directory record Official record
Conditions
Colorectal Cancer, Social Determinants of Health
Interventions
Paired Screening Intervention
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Lowell, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Not applicable Interventional

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

NCT04030507
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

NCT03759236
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Health Messaging via SMS, CDC Health Pamphlets
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

Cancer Stem Cell High-Throughput Drug Screening Study

NCT02654964
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Combination Drug Therapy
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 20, 2026, 5:37 PM EDT
Recruiting No phase listed Observational

Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai

NCT07220863
View directory record Official record
Conditions
Breast Cancer Awareness
Interventions
Not listed
Lead sponsor
Feminai
Industry
Eligibility
25 Years to 75 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

The Northern-European Initiative on Colorectal Cancer

NCT00883792
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy
Procedure
Lead sponsor
Oslo University Hospital
Other
Eligibility
55 Years to 64 Years
Enrollment
95,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2036
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin

NCT02141906
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Oncozene-DEB-TACE
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 20, 2026, 5:37 PM EDT
Completed No phase listed Observational

Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

NCT04968548
View directory record Official record
Conditions
Lung Cancer
Interventions
Blood collection
Procedure
Lead sponsor
Nucleix Ltd.
Industry
Eligibility
50 Years to 80 Years
Enrollment
6,182 participants
Timeline
2021 – 2025
U.S. locations
27
States / cities
Encinitas, California • Lakewood, Colorado • West Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Recruiting Not applicable Interventional

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

NCT05057702
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent, Ependymoma, Ependymoma Malignant, Ependymoma of Brain
Interventions
Specialized Tumor Board Treatment Plan, Combinations
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Months to 39 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Interventions to Decrease Health Information Avoidance

NCT06972667
View directory record Official record
Conditions
Health Information Avoidance
Interventions
Video to promote colonoscopy, Video to promote screening for colorectal cancer with home tests
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
45 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma

NCT05458869
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
HPV Self-Collection, Interview, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
25 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 20, 2026, 5:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

NCT05694559
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Genetic Testing and Counseling, Screening Form
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Not applicable Interventional

An Upstream Palliative Care Intervention for Rural and African-American Advanced Cancer Family Caregivers

NCT03464188
View directory record Official record
Conditions
Cancer, Metastatic, Family Members
Interventions
Project Cornerstone
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Recruiting No phase listed Observational

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

NCT01109420
View directory record Official record
Conditions
Non-Medullary Thyroid Cancer
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Recruiting No phase listed Observational

Clinical Pre-screening Protocol for Ovarian Cancer

NCT03877796
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Drug Response Predictor® (DRP)
Device
Lead sponsor
Allarity Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Recruiting Not applicable Interventional

CHAMP Lung Cancer Screening Program

NCT07572773
View directory record Official record
Conditions
Lung Cancer, Early Lung Cancer Detection
Interventions
DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test, Low-Does CT Scan
Diagnostic Test
Lead sponsor
Jill Kolesar
Other
Eligibility
50 Years to 77 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Iowa City, Iowa • Waterloo, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tribally Engaged Approaches to Lung Screening (TEALS)

NCT04948060
View directory record Official record
Conditions
Lung Cancer
Interventions
Enhanced lung cancer screening services
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
50 Years to 80 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion

NCT03598166
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Septin9
Diagnostic Test
Lead sponsor
Peter S. Liang, MD MPH
Federal
Eligibility
50 Years to 75 Years
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 20, 2026, 5:37 PM EDT